The Power of T Cells
Immunocore, Genentech Seal Multitarget, High-Dollar Deal
By Nuala Moran
Wednesday, July 3, 2013
LONDON Fourteen years of pursuing the objective of breaking T-cell tolerance to cancer cells has finally paid off for Immunocore Ltd. in a multitarget deal with Genentech Inc. (now part of Roche AG) worth a potential $320 million or more per program, plus royalties.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.